Vigilant Biosciences
  • Solutions
    • BeVigilant™ OraFusion System
  • Resources
    • Provider Resources
    • Patient Resources
  • About
    • Leadership
    • Careers
  • News
  • Contact
  • en_USEN
    • de_DEDE
    • it_ITIT
Select Page
Vigilant Biosciences Receives Breakthrough Device Designation from FDA for Point-of-Care Test to Aid in the Early Detection of Oral Cancer

Vigilant Biosciences Receives Breakthrough Device Designation from FDA for Point-of-Care Test to Aid in the Early Detection of Oral Cancer

by vigilantbio | Apr 27, 2023 | Press Release

LAKEWAY, Texas (April 27, 2023) — Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection of oral cancer, is proud to announce receipt of Breakthrough Device Designation from the Food and Drug...

Latest News

  • Vigilant Biosciences Introduces the BeVigilant OraFusion System in GermanySeptember 19, 2023
  • The First Step to Enhancing Oral Cancer Detection: Recognizing Risk Factors and SymptomsSeptember 12, 2023
  • The Consequences of a Missed Oral Cancer DiagnosisAugust 1, 2023
  • The Limitations of Standard Oral Cancer Screening MethodsJuly 17, 2023
  • Challenges in the Early Detection of Oral CancerJune 7, 2023
  • Follow
  • Follow

Follow Us

Follow Us

  • Follow
  • Follow

Provider Resources

Patient Resources

About

Leadership

Careers

News

Contact

Vigilant Biosciences Logo, White

Privacy Policy | Terms of Use

© 2023 Vigilant Biosciences
en_US EN
en_US EN
it_IT IT
de_DE DE
tr_TR TR
pt_PT PT
nl_NL NL
fr_FR FR
es_ES ES